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Abstract
Background—Acute intestinal infection leads to persistent intestinal smooth muscle 
hypercontractility and pain hypersensitivity after resolution of the infection in animal models. We 
investigated whether post-infectious irritable bowel syndrome (PI-IBS) is associated with 
abnormalities in phasic contractions of the colon, smooth muscle tone and pain sensitivity 
compared to non-PI-IBS (NI-IBS) or healthy controls (HC).
Methods—218 Rome III positive IBS patients and 43 healthy controls participated. IBS patients 
were designated PI-IBS if their IBS symptoms began following an episode of gastroenteritis 
characterized by 2 or more of: fever, vomiting, or diarrhea. Pain threshold to phasic distentions of 
the descending colon was assessed using a barostat. Colonic motility was assessed with the 
barostat bag minimally inflated to the individual operating pressure (IOP), at 20 mmHg above the 
IOP, and following a test meal. IBS symptom severity and psychological symptoms were assessed 
by the IBS Severity Scale (IBS-SS) and the Brief Symptom Inventory-18 (BSI-18).
Key Results—Twenty-two (10.1%) met criteria for PI-IBS. Both IBS and HC groups showed a 
significant increase in motility index during intraluminal distention and following meals. The 
magnitude of the response to distention above (orad to) the balloon was significantly greater in PI-
IBS compared with NI-IBS (p<0.05) or HC (p<0.01). Differences between PI-IBS and NI-IBS 
were not significant for IBS symptom severity, pain threshold, barostat bag volumes, or any 
psychological score on the BSI-18.
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Conclusions & Inferences—Patients with PI-IBS have greater colonic hypercontractility than 
NI-IBS. We speculate that sustained mild mucosal inflammation may cause this colonic 
irritability.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by frequent 
abdominal pain accompanied by diarrhea or constipation. These symptoms are thought to be 
due to gut motor hyper-reactivity and enhanced visceral pain sensitivity [1]. Psychosocial 
factors have also been implicated in the clinical expression of IBS [2]. A newly recognized 
risk factor for IBS is infectious gastroenteritis [3–9].
Most people with food or water borne gastrointestinal infections recover completely 
following resolution of the acute infection, but a significant proportion (3.7–36%) go on to 
develop chronic gastrointestinal symptoms consistent with IBS and these patients are 
designated as having post-infectious IBS (PI-IBS) [3]. The most common causative agents 
identified to date are Salmonella, Shigella, and Campylobacter [7–9], and the predominant 
bowel pattern noted is diarrhea predominant IBS (IBS-D) [7].
Several studies have evaluated risk factors for the development or maintenance of PI-IBS 
and identified female gender, psychological symptoms, and elevated levels of inflammatory 
markers as significantly associated with PI-IBS [3]: First, females were shown to be at 
higher risk for PI-IBS in multiple studies [7–9]. Second, two studies addressed the role of 
psychological symptoms but came to different conclusions. In one study, patients with PI-
IBS showed higher scores for anxiety and depression compared with individuals who had no 
IBS symptoms 3 months following acute infection [7], whereas another study failed to 
identify anxiety or depression as an independent predictor of PI-IBS [10]. Third, a mild 
transient gut inflammation led to long-term change of visceral hypersensitivity in an animal 
model of PI-IBS [11]. In another animal study, persistent intestinal smooth muscle 
hypercontractility was present after resolution of chemically induced inflammation [12]. It 
has been reported that colonic transit is accelerated in patients with PI-IBS compared to 
controls [13], but differences in phasic colon motility and smooth muscle tone have not been 
studied in humans with PI-IBS. Last of all, PI-IBS patients show increased numbers of 
inflammatory cells and 5HT-containing enterochromaffin (EC) cells in the rectal mucosa [7, 
14, 15], increased gut permeability [14, 15] and increased sensitivity to rectal distention [13, 
16] compared to control subjects.
Thus, except for psychological symptoms, there are consistent findings in humans for the 
role of other risk factors for PI-IBS. The aims of this study were to investigate whether PI-
IBS is associated with abnormalities in phasic contractions of the colon, smooth muscle 
tone, pain sensitivity, bowel symptoms, or psychological symptoms compared to IBS 
patients with a non-infectious etiology for IBS (NI-IBS) and healthy controls.
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A preliminary report on this study was published in 2008 [17], which described the test 
procedures for the assessment of phasic motility, muscle tone, pain sensitivity, and 
psychological symptoms. The aims of the 2008 publication were to describe the contribution 
of pain sensitivity, colon motility, smooth muscle tone, and psychological symptoms to the 
severity of IBS symptoms and altered bowel habits. PI-IBS patients were not separated out 
from other IBS patients in that report, which described data for 129 of IBS patients and 30 
of healthy subjects included in the current analysis.
Subjects were recruited by advertisements or physician referrals and screened by telephone. 
The study population consisted of 258 patients with a prior physician diagnosis of IBS who 
fulfilled Rome III criteria for IBS [18] and had current IBS symptoms (abdominal pain or 
discomfort at least one-fourth of the time in the last 3 months). Exclusion criteria were a 
history of gastrointestinal surgery (other than appendectomy or cholecystectomy), 
inflammatory bowel disease, celiac disease, lactose malabsorption, heart disease or diabetes 
mellitus, and pregnant or suffering from any acute infectious disease at the time of study.
According to bowel habit reported by patients, patients were classified by Rome III 
guidelines [18] into three subgroups: IBS-D defined as loose (mushy) or watery stool ≥25% 
and hard or lumpy stool <25% of bowel movements, IBS-C defined as hard or lumpy stool 
≥25% and loose or watery stools <25% of bowel movements, and IBS-mixed (IBS-M) 
defined as loose or watery stools ≥25% of the time plus hard or lumpy stools ≥25% of the 
time.
PI-IBS was defined by retrospective questionnaire as the acute onset of new IBS symptoms 
in an individual who had not previously met the Rome criteria for IBS, if they reported 2 or 
more of the following symptoms immediately following an acute illness: fever, vomiting, 
diarrhea, or a positive bacterial stool culture according to the previous report [19]. Forty of 
258 patients with IBS were excluded because they responded “unknown” to the question on 
whether IBS symptoms were preceded by infectious gastroenteritis.
The control population consisted of 43 subjects with no recurring gastrointestinal symptoms. 
Exclusion criteria for controls were average stool frequency of less than 3/week or more 
than 3/day, abdominal pain, or use of a laxative or anti-diarrheal agent on more than two 
occasions over the prior year, history of alcohol or substance abuse, a psychiatric diagnosis, 
or any of the medical conditions listed above for the IBS patients. The study was approved 
by the Institutional Review Board of the University of North Carolina (UNC), and all 
subjects provided written informed consent.
Study Design
Subjects were admitted to the General Clinical Research Center at the University of North 
Carolina for a 24–30 hour period. They were asked to fast for at least 4 hours prior to 
reporting for testing. On the day of admission, the study nurse took a medical history and 
performed a physical examination, and the findings were reviewed by study physicians to 
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ascertain whether the participants were eligible for the study. After screening for eligibility, 
the following questionnaires were completed: The Irritable Bowel Syndrome Severity Scale 
(IBS-SSS) [20], the IBS-QOL [21, 22], and the Brief Symptom Inventory-18 (BSI-18) [23]. 
A low fiber meal was consumed at approximately 5:00 pm. Day 1 ended with a bowel 
cleanout consisting of 1.5 oz of Fleet’s phosphosoda consumed at 6:00 pm and repeated at 
9:00 pm.
Colonic Sensory and Motility Testing
All physiological testing was performed on day 2 according to the protocol shown in Figure 
1. On the morning of day 2 at approximately 8:00 AM, the barostat catheter was placed into 
the descending colon by sigmoidoscope. Following catheter placement, the subject rested for 
90 min before testing began. The motility catheter (Model C7-CB-0026, Mui Scientific 
Mississauga, Ontario, Canada) is 5 mm in outside diameter. It includes four small catheters 
used to measure pressures 2.5 and 5 cm from the proximal and distal edges of the bag. A 10 
cm long, 600 mL capacity polyethylene bag (Model CT-BP600R, Mui Scientific) was 
attached to the surface of the motility catheter and tied with surgical thread. The barostat is 
a computer-controlled pump (Distender II model, G&J Electronics, Willowdale, Ontario, 
Canada) used for testing sensory thresholds and smooth muscle tone in the lumen of the 
bowel. The pneumohydraulic pump (eight-channel hydraulic capillary infusion system, 
Arndorfer Inc, Greendale, WI) uses a tank of compressed air to force degassed sterile water 
from a reservoir through four capillary (very small diameter) catheters that are connected to 
four pressure transducers. Sample distentions were then performed during which the barostat 
bag was inflated in a stepwise fashion by increasing bag pressure by 4 mmHg every 15 
seconds until the subject reported moderate pain (rating of 3 on a 0–5 scale). The sample 
distentions served three purposes: (1) to insure that the barostat bag was unfolded; (2) to 
teach the subject how to use the rating scale to describe the intensity of colonic sensations; 
and (3) to decrease anticipatory anxiety. The barostat bag was then slowly inflated with 50 
ml of air and the pressure was allowed to equilibrate for 3 minutes. The average bag 
pressure during the last 15 seconds defined the individual operating pressure (IOP) [17, 24], 
which is the minimum pressure required to overcome mechanical forces and inflate the bag 
with 50 ml of air. Next, pain thresholds were assessed using the ascending method of limits 
(AML) [24]. Phasic distentions were 30-seconds in duration and were separated by 30 
second rest intervals starting at the IOP and progressively increasing in 2 mmHg steps until 
either the subject requested the research nurse to stop the protocol or 48 mmHg was reached. 
The pain threshold was defined as the amount of pressure above IOP at which the subject 
first reported moderate pain (absolute distending pressure minus the IOP). If the subject 
reached 48 mmHg without reporting moderate pain, the pain threshold was defined as 50 
mmHg minus the IOP. The urge threshold was defined analogously. After measuring 
sensory thresholds, there was a 15 min rest period.
Phasic contractions were measured from the perfusion ports above and below the bag under 
the following conditions: (a) during the fasting baseline for 10 min at the IOP, (b) during 
distention for 10 min at a pressure of IOP+20 mmHg, (c) during a recovery period after 
intraluminal distention for 15 min at the IOP, and (d) following the meal for 30 min at the 
IOP. These tracings were visually screened to exclude artifact, defined as wave amplitudes 
Kanazawa et al. Page 4













less than 5 mmHg or with durations less than 6 sec. The beginning and ending inflection 
points for each individual contraction were identified visually and the area under the curve 
was calculated using computer software (Insight System, Sandhill Scientific, Highlands 
Ranch, CO). These areas were added together, then divided by recording time in seconds 
(excluding the time occupied by movement artifact), and multiplied by 100. Separate 
motility indices (MI) were calculated for the two perfusion ports above the balloon and the 
two ports below the balloon.
Average barostat bag volumes in each period were recorded as a measure of smooth muscle 
tone [24]. Muscle tone was measured during the fasting baseline, recovery period after 
intraluminal distention, and following the meal. The average volume required to maintain 
the barostat bag at a constant pressure was recorded in successive 5 minute blocks; this 
constitutes an index of smooth muscle tone.
The test meal was standardized and contained 810 kcals and 38 grams of fat. Subjects were 
asked to consume the meal within 10 minutes. Phasic and tonic motility were recorded for a 
30-minute period following the test meal (Figure 1). Details of all test procedures and 
descriptions of the questionnaires are given in the 2008 publication [17].
Data Analysis
Because the data were not normally distributed, comparisons between groups were made 
using the Kruskal-Wallis test, followed by Mann-Whitney U test for paired comparisons. A 
Bonferroni correction was also applied to correct for multiple comparisons. For all analyses, 
a p-value of 0.05 defined statistical significance. Although this is a large enough study to be 
reported comparing between patients with and without PI-IBS on physiological findings, the 
available samples were unequal in size (N=22 for PI-IBS, N=181 for NI-IBS and N=43 for 
controls), and consequently the statistical power of between group comparisons varied. To 
compensate for this limitation, we identified the minimum Z-score for a Mann-Whitney U 
test involving the smallest group (PI-IBS) that was significant at P <0.05 and interpreted 
other comparisons as statistically significant only if they exceeded the critical value.
RESULTS
Characteristics of the eligible samples are shown in Table 1. Among the 218 IBS patients, 
22 (10.1%) met criteria for PI-IBS. There were no differences among HC, PI-IBS, and NI-
IBS for female ratio, age, or race/ethnicity. Twenty PI-IBS, 181 NI-IBS, and 34 HC 
underwent the colonic motility tests. No obvious mucosal abnormality or inflammation was 
confirmed in these subjects by colonoscopy. No serious adverse events were observed.
There was no significant difference in the proportion who were females or in the proportion 
with subtypes of bowel habit between PI-IBS and NI-IBS (Table 1). Both PI-IBS and NI-
IBS patients scored significantly higher on the overall score and all subscales of the IBS-
SSS and significantly lower on the IBS-QOL compared to HC (Table 1). Both PI-IBS and 
NI-IBS also scored significantly higher than HC on the BSI-18 global severity index for 
psychological distress and the somatization, depression and anxiety subscales. However, 
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there were no significant differences between patients with PI-IBS and NI-IBS on these 
variables (Table 1).
Pain Sensitivity and Urgency to Defecate
Both the PI-IBS and NI-IBS had significantly lower thresholds for pain and urgency to 
defecate compared to HC. Compared to NI-IBS, the PI-IBS failed to show significantly 
lower thresholds for pain or urge (Table 2).
Smooth Muscle Tone Measured by Barostat Bag Volume
PI-IBS patients showed significantly lower bag volumes than HC at baseline (Table 2 and 
Figure 2). There was no significant difference in bag volume during the baseline period 
between PI-IBS and NI-IBS. Muscle tone was not measured during distention because 
barostat bag volumes during distention reflect compliance rather than tone. Barostat bag 
volumes during recovery from distention were approximately the same as during baseline 
and showed no significant difference between PI-IBS and NI-IBS (Table 2). As shown in 
Figure 2, both HC and IBS groups showed a statistically significant and profound decrease 
in bag volumes following the meal. The magnitude of this change in muscle tone was not 
significantly different among PI-IBS, NI-IBS and HC.
Phasic Colonic Motility
When tested under baseline conditions (fasting, no intraluminal distention), the motility 
index for phasic contractions was no different among HC, NI-IBS and PI-IBS patients 
(Table 2).
As shown in Figure 3A, both IBS and HC groups showed a significant increase from 
baseline in motility index recorded from perfusion ports above the balloon during 
intraluminal distention. The magnitude of this increase was significantly greater in PI-IBS 
compared with NI-IBS (p<0.05) and HC (p<0.01). The colonic phasic motility response to 
distention in NI-IBS was significantly greater than that in HC (p<0.05). The increase in 
motility index from baseline to distention was significantly greater in PI-IBS (504% (110 to 
1117%), median with inter quartile range) compared with NI-IBS (144% (21 to 483%), 
p<0.05) and HC (40% (−16 to 301%), p<0.01). Both IBS and HC groups showed a 
significant increase from baseline in motility index during intraluminal distention at the 
distal site (Figure 3B and Table 2). However, the magnitude of this increase was not 
significantly different among PI-IBS, NI-IBS and HC groups.
During the recovery period following intraluminal distention at the proximal site of the 
balloon, the motility index in PI-IBS was greater compared to NI-IBS and HC but the 
difference was not statistically significant (Figure 3A). The motility index at the distal site in 
PI-IBS was not significantly greater compared to HC or NI-IBS during the recovery period 
(Figure 3B).
As shown in Figure 3A and 3B, both HC and IBS groups showed significant increases in 
motility following the meal compared to baseline. The postprandial motility index recorded 
from perfusion ports below the balloon but not above the balloon, was significantly greater 
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in NI-IBS compared to HC (p<0.05, Figure 3B). However, the meal-stimulated increase in 
phasic contractions at the distal site in PI-IBS (174% (−1 to 317%)) was not significantly 
greater compared to NI-IBS (87% (18 to 376%)) or HC (87% (14 to 226%)).
DISCUSSION
This is the first study to compare physiological findings on colonic motility and visceral 
sensitivity between patients with a preceding infectious episode before the onset of IBS (PI-
IBS) compared to those without an infectious episode (NI-IBS). This large, carefully 
conducted study yielded important and novel findings: Patients with PI-IBS showed more 
phasic contractions of the colon during intraluminal distention compared to NI-IBS and 
healthy controls, a significant increase in smooth muscle tone compared to HC at baseline, 
and a tendency for muscle tone to be higher in PI-IBS than in NI-IBS at baseline. However, 
there was no difference in IBS symptom severity, psychological symptoms, or visceral 
sensitivity to colonic distention between patients with PI-IBS and those with NI-IBS (Table 
1). Prevalence of PI-IBS in the unselected patients with IBS in the present study is similar 
with the previous reports from epidemiological studies [25]. In addition, the proportion of 
subtypes of bowel habit in our patients with PI-IBS was in accordance with the previous 
findings from a long-term cohort study [26].
Colonic Motility Responses in PI-IBS
The pathophysiological mechanisms involved in PI-IBS are currently unknown. We have 
previously reported that IBS patients show hypercontractility during colonic distention 
independent of their bowel habit subtype [17]. It has been reported that rectal 
hypersensitivity and accelerated whole gut transit were exhibited in both patients with PI-
IBS and patients who returned to normal bowel habit following an infectious episode [13]. 
However, differences in gut motor and sensory function has not been evaluated between PI-
IBS and NI-IBS until now.
Our findings are consistent with animal studies showing that transient enteric infection can 
lead to persistent gut dysmotility in nematode-infected mice [11]. Animal studies have 
demonstrated that inflammation-induced intestinal muscle hypercontractility persists even 
after resolution of the inflammation [12, 27] and that increases in muscle contractility are 
associated with increases in intestinal 5-HT and infiltration of immunocytes [28]. Several 
reports on histologic and immunohistochemical analyses in the intestinal mucosa [7, 14, 29] 
suggest that subtle morphologic changes involving lymphocytes, mast cells, 
enterochromaffin (EC) cells which contain serotonin, and enteric nerves may be associated 
with IBS symptoms. This low-grade intestinal mucosal inflammation along with mast cell 
hyperplasia might contribute to the development and perpetuation of abnormal motility 
patterns and visceral hypersensitivity in IBS by increasing mucosal 5-HT release and 
availability. Gut inflammation increases the number of EC cells, which is mediated by T 
lymphocytes [30], as has been reported in PI-IBS [19], and inflammation reduces SERT 
[31]. In addition, 5-HT spontaneous secretion is correlated with mast cell counts and the 
severity of abdominal pain in patients with IBS [32]. Interestingly, the 5-HT3 antagonist 
alosetron actually decreased rectal tone in patients with diarrhea-predominant IBS [33].
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Colonic Visceral Sensitivity and Psychological Factors in PI-IBS
Even mild acute colitis can induce long-lasting visceral hyperalgesia in a rat model [34]. 
Moreover, intestinal effluents from IBS patients activate visceral sensory afferent pathways 
when applied to the mucosa of an animal model, and this effect is mediated by proteases 
released by activated mast cells [35]. There is also a positive correlation between the number 
of activated mast cells in close proximity to nerve endings and the severity of abdominal 
pain in IBS patients [36]. Consequently, in the present study PI-IBS patients were expected 
to have a lower pain threshold than NI-IBS, but the groups were not found to be 
significantly different. This lack of effect could be due to low statistical power.
Cognitive and psychological factors also influence pain reporting: We have shown that pain 
threshold in patients with IBS are significantly correlated with somatization and anxiety 
[37], and brain imaging studies reveal that visceral stimuli activate affective and/or cognitive 
regions such as the dorsal anterior cingulate cortex (dACC) in patients with IBS [38, 39]. 
These centrally mediated processes may play an important role in the pathophysiology of 
visceral sensitivity in IBS, and this effect may be independent of gastroenteritis. This would 
be consistent with the findings of this study which showed significant elevations for both 
groups of IBS patients on all subscales of the BSI-18 but no differences in pain or urge 
thresholds between PI-IBS and NI-IBS.
Study Limitations
The small number of PI-IBS cases identified in this study resulted in modest statistical 
power; with a larger sample of PI-IBS patients the trend towards a difference in baseline 
muscle tone between PI-IBS and NI-IBS might be found to be statistically significant. In the 
present study, only a 10-min baseline period for the motility measurement was set to avoid a 
prolonged experimental time. Therefore, the motility recordings were carefully performed 
by observing the baseline stabilization after a sufficient rest (over 30 minutes).
A second limitation was that the diagnosis of PI-IBS was based on retrospective reports of 
an episode of gastroenteritis preceding the onset of IBS symptoms and the absence of IBS 
preceding this episode of gastroenteritis. We do not think this was a major source of case 
misclassification because the rate of PI-IBS (10.1% of IBS patients) was similar to what has 
been reported in the literature (6% to 17%) [25]. Moreover, we used published criteria for 
inferring the presence of PI-IBS [19] although detailed features of the acute infectious 
episode (e.g. duration of diarrhea, weight loss, and bloody stool) which may be associated 
with the risk factors of PI-IBS [10] were not evaluated. It is noted that no difference was 
found in characteristics of IBS samples for the analyses between patients already reported 
elsewhere [17] and the additional patients including age, female ratio, race/ethnicity, IBS 
symptom severity or prevalence of PI-IBS in the present study (data were not shown).
A third limitation is that a variable amount of time – often several years – elapsed between 
the episode of infectious gastroenteritis and the subject’s participation in this study, and 
some potential moderators of the risk of developing PI-IBS such as re-exposure to 
gastrointestinal pathogens and changes in psychological symptoms of anxiety and 
depression may have occurred during this interval. This would reduce the chances of 
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identifying a significant association between these variables and the occurrence of PI-IBS. 
However, when a significant difference between PI-IBS and NI-IBS such as the difference 
in phasic motility response to distention is observed years after the enteric infection, this can 
be interpreted as evidence that the past enteric infection was the cause.
The present study would have been enhanced if we had collected mucosal biopsies or stool 
specimens and tested for increased numbers of EC cells, immune cells such as mast cells, or 
inflammatory mediators in the gut mucosa. It has been reported that a greater number of EC 
cells is associated with visceral hypersensitivity in patients with IBS [40]. Experimental 
studies in animals support the findings that PI-IBS shows colonic hypercontractility during 
noxious stimulation of the gut [12, 27], and our study confirms this in human IBS patients. 
Further prospective observations of the relationships between such a physiological 
exacerbation and changes in mucosal immunocyte infiltration [13, 14], epithelial 
permeability [15] and composition of gut microbiome [41, 42] are needed to confirm the 
hypothesis that the exaggerated motility responses to distention are mediated by persisting 
immune activation.
Conclusions
PI-IBS is considered to be a good model for investigating the etiology and pathophysiology 
of IBS because PI-IBS identifies a more homogeneous subset of patients. This study shows 
that approximately 10% of IBS patients have an infectious etiology and that the principal 
physiological difference between PI-IBS and NI-IBS is greater colonic hypercontractility 
during intraluminal distention. This pattern of hypercontractility was not limited to one 
bowel habit subtype of IBS, although others have found diarrhea to be more common than 
constipation in PI-IBS. There were no significant differences between PI-IBS and NI-IBS in 
IBS symptom severity, psychological symptoms, resting smooth muscle tone or visceral 
pain sensitivity even though IBS patients in general (both PI-IBS and NI-IBS) were 
significantly different from healthy controls in these regards. This suggests that the 
physiological mechanisms for symptoms are generally similar for PI-IBS and NI-IBS and 
that PI-IBS is a part of IBS rather than being a distinctly different disorder. It remains to be 
investigated whether PI-IBS patients will respond to different treatments than other types of 
IBS. The most likely candidate for a PI-IBS-specific treatment is a motility agent or a mast 
cell stabilizer.
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IBS irritable bowel syndrome
PI-IBS post-infectious irritable bowel syndrome
NI-IBS non-post-infectious irritable bowel syndrome
IBS-SS Irritable Bowel Syndrome Severity Scale
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BSI Brief Symptom Inventory
AML ascending method of limits
IOP individual operating pressure
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The aim of the study was to investigate whether post-infectious IBS (PI-IBS) is 
associated with colonic motility and sensory abnormalities compared to non-PI-IBS (NI-
IBS) or healthy controls (HC).
Colonic motility and visceral pain threshold to intraluminal distentions were compared 
using manometric and barostat devices.
PI-IBS patients demonstrated increased colonic contractility during distention compared 
to NI-IBS and HC. PI-IBS and NI-IBS patients were similar in pain threshold, IBS 
symptom severity, IBS-Quality of Life impact, and psychological symptoms suggesting 
that PI-IBS is not a distinct subtype of IBS.
Modulation of gut irritation and motility agents should be taken into account for 
management of IBS.
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The sequence of events during the study. AML, ascending method of limits; IOP, individual 
operating pressure.
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Colonic tonic motility responses. Mean barostat bag volumes with standard deviation were 
shown during baseline, recovery and postprandial periods. Muscle tone was not measured 
during distention because barostat bag volumes during distention reflect compliance rather 
than tone. Open bars, healthy controls (HC); hatched bars, non-post-infectious-IBS (NI-
IBS); closed bars, post-infectious IBS (PI-IBS). *p<0.05 vs. HC.
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Colonic phasic motility responses. Mean motility indices recorded from perfusion ports 
above the balloon (A) and bellow the balloon (B) placed into the descending colon with 
standard deviation were shown during the baseline (at IOP), distention (at IOP+20 mmHg), 
recovery (at IOP) and postprandial periods (at IOP). Open bars, healthy controls (HC); 
hatched bars, non-post-infectious-IBS (NI-IBS); closed bars, post-infectious IBS (PI-IBS). 
*p<0.05, **p<0.01 vs. HC; †p<0.05 vs. NI-IBS.
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Table 1
Characteristics of the participants
HC NI-IBS PI-IBS
Number (female%) 43 (81%) 196 (83%) 22 (82%)
Age (yrs) 38 ± 13 33 ± 11 36 ± 11
Subtypes of bowel habit
 Diarrhea – 65 (33%) 10 (46%)
 Mixed – 85 (43%) 8 (36%)
 Constipation – 32 (16%) 3 (14%)
 Unspecified – 14 (7%) 1 (4%)
IBS-SSS (overall) 29 ± 52 276 ± 90** 261 ± 94**
 Pain intensity 3 ± 11 46 ± 25** 49 ± 26**
 Pain duration 5 ± 12 47 ± 23** 48 ± 26**
 Abdominal bloating 3 ± 8 47 ± 29** 36 ± 32**
 Dissatisfaction of bowel habit 17 ± 29 77 ± 23** 73 ± 26**
 Disturbed daily activity 4 ± 14 59 ± 28** 55 ± 31**
IBS-QOL 99 ± 3 69 ± 21** 70 ± 20**
BSI-18 general severity index 42 ± 8 51 ± 10** 53 ± 10**
 Somatization 45 ± 6 53 ± 8** 54 ± 9**
 Depression 46 ± 8 51 ± 11** 52 ± 12*
 Anxiety 43 ± 6 50 ± 9** 50 ± 11**
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Table 2
Sensory thresholds and colonic motility responses.
HC NI-IBS PI-IBS
Pain threshold (mmHg) 40 (30–42) 30 (20–38)** 32 (13–42)**
Urge threshold (mmHg) 34 (22–42) 17 (11–30)** 17 (9–38)**
IOP (mmHg) 8 (6–10) 10 (8–12) 8 (7–10)
Barostat bag volume (mL)
 Baseline at IOP 50 (20–84) 36 (18–56) 36 (15–56)*
 Recovery at IOP 42 (20–80) 32 (17–59) 40 (14–89)
 Postprandial period at IOP 17 (11–27) 15 (12–20) 14 (10–20)
Motility index above the balloon
 Baseline 310 (196–546) 263 (143–677) 499 (129–792)
 Distention 407 (300–758) 800 (448–1308)* 1011 (562–3357)**,†
 Recovery 369 (206–526) 345 (151–804) 633 (345–1267)
 Postprandial period 543 (295–901) 446 (223–835) 510 (235–685)
Motility index below the balloon
 Baseline 141 (74–274) 187 (107–397) 122 (71–535)
 Distention 462 (234–614) 345 (180–703) 508 (118–758)
 Recovery 186 (71–325) 310 (121–426) 204 (127–251)
 Postprandial period 286 (139–418) 434 (202–628)* 239 (118–381)







Neurogastroenterol Motil. Author manuscript; available in PMC 2016 February 03.
